Zhejiang Wolwo Bio-Pharmaceutical Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 5/6
Zhejiang Wolwo Bio-Pharmaceutical has been growing earnings at an average annual rate of 2.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 8.8% per year. Zhejiang Wolwo Bio-Pharmaceutical's return on equity is 12.1%, and it has net margins of 34.5%.
Wichtige Informationen
2.5%
Wachstumsrate der Gewinne
2.5%
EPS-Wachstumsrate
Pharmaceuticals Wachstum der Industrie | 10.9% |
Wachstumsrate der Einnahmen | 8.8% |
Eigenkapitalrendite | 12.1% |
Netto-Marge | 34.5% |
Letzte Ertragsaktualisierung | 30 Sep 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.'s (SZSE:300357) P/E Is Still On The Mark Following 39% Share Price Bounce
Sep 30These 4 Measures Indicate That Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Is Using Debt Reasonably Well
Sep 26Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) Has Announced That Its Dividend Will Be Reduced To CN¥0.185
Jun 30Investor Optimism Abounds Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357) But Growth Is Lacking
May 27Calculating The Fair Value Of Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SZSE:300357)
May 07Is Zhejiang Wolwo Bio-Pharmaceutical (SZSE:300357) A Risky Investment?
Mar 22Aufschlüsselung der Einnahmen und Ausgaben
Wie Zhejiang Wolwo Bio-Pharmaceutical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
---|---|---|---|---|
30 Sep 24 | 905 | 312 | 427 | 122 |
30 Jun 24 | 891 | 311 | 410 | 122 |
31 Mar 24 | 881 | 317 | 401 | 118 |
31 Dec 23 | 848 | 310 | 384 | 112 |
30 Sep 23 | 870 | 292 | 380 | 108 |
30 Jun 23 | 893 | 316 | 379 | 107 |
31 Mar 23 | 882 | 328 | 365 | 104 |
01 Jan 23 | 896 | 349 | 361 | 106 |
30 Sep 22 | 888 | 391 | 357 | 103 |
30 Jun 22 | 849 | 372 | 339 | 100 |
31 Mar 22 | 841 | 359 | 341 | 95 |
31 Dec 21 | 808 | 338 | 336 | 88 |
30 Sep 21 | 765 | 324 | 320 | 78 |
30 Jun 21 | 724 | 319 | 303 | 75 |
31 Mar 21 | 691 | 308 | 283 | 70 |
31 Dec 20 | 636 | 278 | 263 | 61 |
30 Sep 20 | 630 | 281 | 257 | 56 |
30 Jun 20 | 624 | 275 | 257 | 48 |
31 Mar 20 | 612 | 274 | 257 | 42 |
31 Dec 19 | 639 | 298 | 259 | 37 |
30 Sep 19 | 615 | 290 | 256 | 29 |
30 Jun 19 | 556 | 259 | 235 | 19 |
31 Mar 19 | 532 | 247 | 222 | 16 |
31 Dec 18 | 501 | 233 | 205 | 12 |
30 Sep 18 | 478 | 227 | 188 | 10 |
30 Jun 18 | 439 | 211 | 171 | 11 |
31 Mar 18 | 411 | 200 | 163 | 9 |
31 Dec 17 | 386 | 186 | 158 | 6 |
30 Sep 17 | 367 | 175 | 156 | 5 |
30 Jun 17 | 344 | 154 | 157 | 0 |
31 Mar 17 | 324 | 139 | 153 | 0 |
31 Dec 16 | 312 | 129 | 151 | 0 |
30 Sep 16 | 303 | 129 | 141 | 0 |
30 Jun 16 | 283 | 121 | 136 | 0 |
31 Mar 16 | 277 | 122 | 130 | 0 |
31 Dec 15 | 267 | 118 | 126 | 0 |
30 Sep 15 | 261 | 116 | 121 | 0 |
30 Jun 15 | 252 | 112 | 118 | 0 |
31 Mar 15 | 247 | 110 | 116 | 0 |
31 Dec 14 | 240 | 100 | 122 | 0 |
30 Sep 14 | 228 | 90 | 121 | 0 |
30 Jun 14 | 211 | 78 | 116 | 0 |
31 Mar 14 | 202 | 68 | 114 | 0 |
31 Dec 13 | 194 | 71 | 102 | 0 |
Qualität der Erträge: 300357 has high quality earnings.
Wachsende Gewinnspanne: 300357's current net profit margins (34.5%) are higher than last year (33.5%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 300357's earnings have grown by 2.5% per year over the past 5 years.
Beschleunigtes Wachstum: 300357's earnings growth over the past year (7.1%) exceeds its 5-year average (2.5% per year).
Erträge im Vergleich zur Industrie: 300357 earnings growth over the past year (7.1%) exceeded the Pharmaceuticals industry -1.2%.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 300357's Return on Equity (12.1%) is considered low.